COVID-19大流行期间慢阻肺急性加重住院变化:按稳定期血嗜酸性粒细胞分层
Differences in hospital admissions for acute exacerbations of COPD during the COVID-19 pandemic stratified by stable-state blood eosinophil count.
PubMed 文献 · Eur Respir J · 2023-10-12
该研究按稳定期血嗜酸性粒细胞计数分层,分析COVID-19大流行期间慢阻肺急性加重住院的变化。结果显示,住院下降仅见于非T2-high患者,且仅见于非嗜酸性粒细胞性急性加重住院。作者提出需对慢阻肺急性加重进行表型分型以实现个体化管理。
要点
- COVID-19大流行期间慢阻肺急性加重住院下降仅见于非T2-high患者。
- 住院下降仅见于非嗜酸性粒细胞性急性加重住院。
- 需对慢阻肺急性加重进行表型分型以支持个体化管理。
核心结论
- COVID-19大流行期间慢阻肺急性加重住院下降仅见于非T2-high患者,且仅见于非嗜酸性粒细胞性急性加重住院。
主要发现
- 按稳定期血嗜酸性粒细胞计数分层后,慢阻肺急性加重住院的下降仅出现在非T2-high患者中。
- 慢阻肺急性加重住院的下降仅见于非嗜酸性粒细胞性急性加重住院。
- 近40%的慢阻肺急性加重与血嗜酸性粒细胞增多相关并涉及2型炎症(T2-high)。
临床怎么用
- 临床应结合稳定期血嗜酸性粒细胞计数识别慢阻肺急性加重表型以支持个体化管理。
- 需在急性加重时进行表型分型以指导慢阻肺急性加重的个体化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hospital admission for exacerbations of COPD fell only in non-T2-high patients during the COVID-19 pandemic and only in non-eosinophilic admissions. Phenotyping of AECOPD, including at time of exacerbation, is needed for personalised management. https://bit.ly/3ZiUtYx Acute exacerbations of COPD (AECOPD) are driven through different triggers, including infection such as viruses and bacteria. However, nearly 40% of exacerbations are associated with a blood eosinophilia and related to type 2 inflammation (T2-high) [1].
来源:Eur Respir J,查看原文。版权归原作者所有。
引用
- Aung, McAuley, Porter, et al. Differences in hospital admissions for acute exacerbations of COPD during the COVID-19 pandemic stratified by stable-state blood eosinophil count. Eur Respir J. 2023. PMID: 37770078. doi:10.1183/13993003.01125-2023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。